Corcept Therapeutics Incorporated (BIT:1CORT)
Italy · Delayed Price · Currency is EUR | Market Cap | 10.69B +63.2% |
| Revenue (ttm) | 727.21M +16.0% |
| Net Income | 47.50M -58.7% |
| EPS | 0.40 -59.3% |
| Shares Out | n/a |
| PE Ratio | 224.99 |
| Forward PE | 19.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 96.06 |
| Day's Range | n/a |
| 52-Week Range | 25.50 - 103.05 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Corcept Therapeutics
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortis... [Read more]
Financial Performance
In 2025, Corcept Therapeutics's revenue was $761.41 million, an increase of 12.79% compared to the previous year's $675.04 million. Earnings were $98.17 million, a decrease of -29.74%.
Financial numbers in USD Financial StatementsNews
Raised Guidance Lifts Corcept to 52-Week High
CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) as well as Cushing...
Corcept Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 32% year-over-year to $256.1 million, driven by strong launches in both endocrinology and oncology. LIFYORLI saw rapid uptake with over 1,300 patients treated, and guidance was raised to $1.1–$1.2 billion for 2026.
Corcept Therapeutics Earnings release: Q2 2026
Corcept Therapeutics released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Corcept Therapeutics Quarterly report: Q2 2026
Corcept Therapeutics has published its Q2 2026 quarterly earnings report on July 29, 2026.
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026....
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 4.9% year-over-year to $164.9M, but net loss reached $31.8M due to launch costs. Lifyorli’s early FDA approval and rapid adoption, plus strong endocrinology growth, led to raised 2026 guidance of $950M–$1.05B.
Corcept Therapeutics Earnings release: Q1 2026
Corcept Therapeutics released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Corcept Therapeutics Quarterly report: Q1 2026
Corcept Therapeutics has published its Q1 2026 quarterly earnings report on April 30, 2026.
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on April 30, 2026....
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics Proxy statement: Proxy filing
Corcept Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
Corcept Therapeutics shares jumped more than 32% to nearly a two-month high on Wednesday after the U.S. health regulator approved its lead drug for treating an aggressive form of ovarian cancer that...
FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporate...
Corcept Therapeutics Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Corcept Therapeutics Incorporated (NASDAQ: CORT). The investigation focus...
REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026
NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ:CORT) investors of the April 21, 2026 deadline to seek the role of lead pl...
Corcept Therapeutics Earnings Call Transcript: Q4 2025
Revenue grew 13% to $761M in 2025, driven by record Cushing's syndrome demand, while net income declined. Regulatory and legal setbacks impacted relacorilant, but strong clinical data and pharmacy transition support future growth.